DO
DOCS.US Doximity Inc
- Market cap
- USD 5.95B
- P/E
- 46.3x
- P/B
- 6.38x
- ROE
- 12.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is DOCS.US undervalued?
Graham numberThe Graham number of Doximity Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Doximity Inc fundamental analysis
No fundamental analysis for Doximity Inc yet.
Doximity Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Doximity Inc
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical m…
Full company profileDoximity Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Doximity Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 85.7M | 116M | 207M | 344M | 419M | 475M | 570M | 645M | 662M |
| Gross Profit | 74.8M | 101M | 176M | 304M | 366M | 425M | 515M | 575M | 564M |
| Operating Income | 6.92M | 22.2M | 53.3M | 114M | 125M | 164M | 228M | 215M | 155M |
| EBITDA | 7.47M | 23.1M | 57.5M | 119M | 143M | 182M | 241M | 264M | 199M |
| Net Income | 7.83M | 29.7M | 50.2M | 155M | 113M | 148M | 223M | 196M | 118M |
| EPS | 0.04 | 0.16 | 0.28 | 0.81 | 0.53 | 0.72 | 1.11 | 0.98 | 0.63 |
| Balance Sheet | |||||||||
| Total Assets | 86.6M | 139M | 252M | 991M | 1.14B | 1.08B | 1.26B | 1.12B | 1.09B |
| Total Liabilities | 37.8M | 138M | 185M | 113M | 171M | 178M | 182M | 173M | 163M |
| Shareholders' Equity | 48.5M | 1.14M | 66.7M | 879M | 966M | 901M | 1.08B | 951M | 928M |
| Cash & Short-term Investments | 62.3M | 86.4M | 143M | 798M | 841M | 763M | 916M | 749M | 713M |
| Total Debt | - | 2.28M | 1.25M | 1.09M | 15.6M | 14.5M | 12.4M | 10.2M | 9.15M |
| Cash Flow | |||||||||
| Operating Cash Flow | 15.3M | 26.2M | 83.0M | 127M | 180M | 184M | 273M | 326M | 271M |
| Capital Expenditure | 1.19M | 4.24M | 4.61M | 5.70M | 6.18M | 5.80M | 6.53M | 8.96M | 4.03M |
| Free Cash Flow | 14.1M | 22.0M | 78.4M | 121M | 173M | 178M | 267M | 317M | 267M |
| Ratios | |||||||||
| ROE | 16.2% | 2,617.7% | 75.2% | 17.6% | 11.7% | 16.4% | 20.6% | 20.6% | 12.7% |
| ROA | 9.0% | 21.4% | 19.9% | 15.6% | 9.9% | 13.7% | 17.7% | 17.4% | 10.8% |
| Net Profit Margin | 9.1% | 25.5% | 24.3% | 45.1% | 26.9% | 31.0% | 39.1% | 30.4% | 17.8% |
| Debt to Equity | - | 2.01x | 0.02x | 0.00x | 0.02x | 0.02x | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Doximity Inc dividends
Doximity Inc has not paid dividends in the last 8 fiscal years.
Who owns Doximity Inc
- Insiders 3.62%
- Institutions 95.88%
- Public & others 0.50%
- Shares outstanding 128M
- Free float 124M
Top funds holding DOCS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Mid-Cap ETF | 4.58M | 2.57% | +0.05% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.87M | 2.17% | -8.14% | Sep 2026 |
| Vanguard Small Cap Index | 2.72M | 1.52% | -10.44% | Sep 2026 |
| Vanguard Explorer Inv | 2.16M | 1.21% | +0.59% | Sep 2026 |
| Smithson Investment Trust Ord | 1.65M | 0.92% | 0.00% | Jan 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.52M | 0.85% | -13.20% | Sep 2026 |
| Invesco S&P MidCap Quality ETF | 1.39M | 0.78% | +0.15% | Oct 2026 |
| Federated Hermes MDT Mid Cap Growth A | 1.30M | 0.73% | -15.12% | Sep 2026 |
| Carmignac Investissement A EUR Acc | 1.00M | 0.56% | -50.00% | Aug 2026 |
| Strategic Advisers Fidelity US TtlStk | 995K | 0.56% | +102.26% | Sep 2026 |
| State Street® SPDR® S&P MIDCAP 400® ETF | 942K | 0.53% | -3.78% | Sep 2026 |
| iShares S&P Mid-Cap 400 Growth ETF | 766K | 0.43% | -0.26% | Oct 2026 |
| State Street SPDR Port S&P 400 Md CpETF | 693K | 0.39% | +0.05% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 676K | 0.38% | +0.24% | Oct 2026 |
| Pacer US Large Cp CA Cows Gr Ldrs ETF | 565K | 0.32% | +0.13% | Oct 2026 |
| Strategic Advisers U.S. Total Stock | 556K | 0.31% | -0.03% | Sep 2026 |
| iShares Russell Mid-Cap ETF | 546K | 0.31% | -0.06% | Oct 2026 |
| Touchstone Small Company A | 531K | 0.30% | -32.41% | Sep 2026 |
| Fidelity Mid Cap Index | 515K | 0.29% | +3.95% | Sep 2026 |
| Fidelity SAI US Quality Index | 481K | 0.27% | +3.40% | Sep 2026 |
Top institutions holding DOCS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 14.3M | 8.02% | +0.35% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 6.39M | 3.58% | -0.11% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.98M | 3.35% | +3.68% | Jun 2026 |
| D. E. Shaw & Co LP | 5.92M | 3.32% | +104.13% | Jun 2026 |
| Two Sigma Investments LLC | 4.65M | 2.60% | +239.18% | Jun 2026 |
| State Street Corp | 4.21M | 2.36% | +4.24% | Jun 2026 |
| The Goldman Sachs Group Inc | 4.09M | 2.29% | +131.85% | Jun 2026 |
| Geode Capital Management, LLC | 3.85M | 2.16% | -2.42% | Jun 2026 |
| Wellington Management Company LLP | 3.14M | 1.76% | +24.72% | Jun 2026 |
| Deutsche Bank AG | 2.89M | 1.62% | -1.00% | Jun 2026 |
| Renaissance Technologies Corp | 2.85M | 1.60% | -6.74% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 2.69M | 1.51% | +459.54% | Jun 2026 |
| Carmignac Gestion | 2.36M | 1.32% | -45.36% | Jun 2026 |
| Federated Hermes Inc | 2.33M | 1.31% | +14.26% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.25M | 1.26% | +2.32% | Jun 2026 |
| Loomis, Sayles & Company LP | 2.19M | 1.23% | +7.33% | Jun 2026 |
| Squarepoint Ops LLC | 2.17M | 1.22% | +180.16% | Jun 2026 |
| Millennium Management LLC | 2.07M | 1.16% | +360.94% | Jun 2026 |
| Amvescap Plc. | 1.92M | 1.08% | +28.07% | Jun 2026 |
| Amundi | 1.90M | 1.07% | +234.39% | Jun 2026 |
Doximity Inc company profile
- Company name
- Doximity Inc
- Ticker
- DOCS.US
- Exchange
- USA Stocks
- Listed since
- Jun 24, 2021
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 880
- Fiscal year end
- March
- Address
- 500 3rd Street, San Francisco, CA, United States, 94107
- Phone
- 650 549 4330
- Website
- doximity.com
About Doximity Inc
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools, including Ask, a HIPAA-compliant AI assistant, to access and apply evidence-based medical information within clinical workflows; Scribe, a HIPAA-compliant, AI-powered clinical documentation tool; Telehealth tools for hospitals and health systems; and AMiON, an on-call scheduling tool. The company primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Doximity Inc management
10- Mr. Jeffrey A. TangneyCo-Founder, CEO & Chairperson · born 1973
- Mr. Siddharth SitaramChief Accounting Officer · born 1978
- Mr. John T. VaughanGeneral Counsel, Corporate Secretary & Chief Compliance Officer · born 1975
- Dr. Steven L. Zatz M.D.President · born 1957
- Mr. Matthew SonefeldtCFO & Principal Financial Officer · born 1980
- Mr. Jey BalachandranChief Technology Officer
- Mr. Perry Scott GoldHead of Investor Relations
- Mr. Bruno MirandaSenior Vice President of Engineering
- Mr. Joel DavisSenior Vice President of Product
- Mr. Ben GreenbergSenior VP & GM Commercial Products